Johns Hopkins Vaccine Initiative 2013 Vaccine Internship Experience at WHO (VIEW) Sample Internship Descriptions
|
|
- Kristian Anthony
- 5 years ago
- Views:
Transcription
1 Johns Hopkins Vaccine Initiative 2013 Vaccine Internship Experience at WHO (VIEW) Sample Internship Descriptions A. Launching of Updated Malaria Vaccine Technology Roadmap & Associated Activities... 2 B. Support to generate a global coverage estimate of children who have received two doses of measles containing vaccine (MCV1 and MCV2)... 3 C. Supporting the Introduction and Use of Vaccines Through the Collection, Analysis and Reporting of Global VPD Surveillance Data... 5 D. Strengthening the evidence- base of WHO immunization policy recommendations Department of Immunization, Vaccines and Biologicals (IVB), Immunization Policy Unit... 6 E. Economics of vaccines and immunizations... 7 F. Support to analyse survey data and develop an article on experiences with obtaining consent for vaccination of school- going children and adolescents... 8 G. The broader economic impact of vaccines P age
2 A. Launching of Updated Malaria Vaccine Technology Roadmap & Associated Activities Mentor: Vasee Moorthy Background: The Malaria Vaccine Technology Roadmap was launched in 2006 at the WHO Global Vaccine Research Forum and established a shared Vision, Strategic Goal (2025) and Landmark (2015) for development of malaria vaccines. The Roadmap also identified 11 Priority Areas in four categories: research, vaccine development, key capacities, policy and commercialization. Through a WHO consultative process, the Roadmap Vision and Strategic Goal(s) are being updated, culminating in review and endorsement by an appropriate WHO mechanism. The update will likely broaden the Roadmap Vision and Strategic Goal(s) to include: a larger geographic scope; older age groups; species beyond P. falciparum; and the need for the vaccine to reduce or prevent transmission in addition to morbidity and mortality. To maintain the relevance of the Roadmap Vision and Strategic Goal(s) as the epidemiological and malaria control status changes over time and to establish new landmarks as promising malaria vaccine candidates advance in development, the update will also include a description of a process for future Roadmap updates. It is anticipated that the updating process will conclude during the second quarter of 2013, culminating in the launch of an updated Roadmap during the third quarter of Scope of Work: The intern project will include assistance in production of technical and communication materials to assist with the launch of the roadmap on the WHO website, and at 1 or more international conferences (targeting the Multilateral Initiative on Malaria meeting in Durban in October 2013 as the launch meeting) The intern will also assist the focal point with follow- on activities after the launch, particularly planning of a process to agree preferred product characteristics to guide early stage R&D of malaria vaccines for 5-10 year development timeframes, and in line with each of the strategic goals to be agreed in the updated roadmap See Skills Necessary: Skills required: Proficiency in word, powerpoint, excel, basic technical background in malaria vaccine development from reading recent reviews, interest in malaria. Preferable: Proficiency in software for desktop publishing to create communications material, French language would be a bonus. 2 P age
3 B. Support to generate a global coverage estimate of children who have received two doses of measles containing vaccine (MCV1 and MCV2) Mentors: Tracey Goodman, Kaushik Bannerjee Background: In August 2009, WHO issued a new recommendation that reaching all children with 2 doses of measles vaccine should be the standard for all national immunization programmes. 1 With regards to the timing of the second dose of measles containing vaccine (MCV2), the WHO position paper states: In countries with ongoing measles transmission and MCV1 delivered at age 9 months, should administer the routine dose of MCV2 at age months. The minimum interval between MCV1 and MCV2 is 1 month. Providing routine MCV2 to children in their second year of life reduces the rate of accumulation of susceptible children and the risk of an outbreak. In countries with low measles transmission (that is, those that are near elimination) and where MCV1 is administered at age 12 months, the optimal age for delivering routine MCV2 is based on programmatic considerations that achieve the highest coverage of MCV2 and, hence, the highest population immunity. Administration of MCV2 at age months ensures early protection of the individual, slows accumulation of susceptible young children and may correspond with other routine immunizations (for example, a DTP booster). If MCV1 coverage is high (>90%) and school enrolment is high (>95%), administration of routine MCV2 at school entry may prove an effective strategy for achieving high coverage and preventing outbreaks in schools. Countries have adopted different schedules for administering MCV2. In 2010, 136 countries reported that they were providing a routine 2nd dose of measles in 1 country MCV2 was provided at 9 months; 43 countries by 2 years of age; 81 countries by 7 years of age; 11 countries by > 7 years of age). This diversity in schedules has hampered the ability of WHO/UNICEF to aggregate data and determine the global coverage of MCV2. Consequently, unlike the other infant vaccines, to date there has never been a WHO/UNICEF Coverage Estimate for MCV2. In light of the new Measles & Rubella Strategic Plan , the absence of an MCV2 coverage estimate must be redressed in order to monitor progress towards elimination of these diseases in 5 regions by The stated milestone is: To achieve at least 95% coverage with both the first and second routine doses of measles vaccine (or measles- rubella- containing vaccine as appropriate) in each district and nationally. It has been proposed that the diversity of MCV2 schedules and the challenge of estimating global coverage could be handled by calculating the proportion of children who have received two doses of MCV by a certain age. This would be similar to the coverage monitoring method like that developed for HPV vaccine (i.e. by individual age cohorts) and require countries to record and report MCV doses given by each year of age. Scope of Work The WHO Immunization, Vaccines & Biologicals (IVB) Department seeks an intern to work under the supervision of WHO technical staff within the (Expanded Programme on Immunization (EPI) team to support two components of work: 1. Collate the reported country data on MCV2: All member states of the United Nations report their immunization data annually to WHO and UNICEF using the Joint Reporting Form (JRF). Since 2000, countries that have MCV2 in their immunization schedules report the age(s) at which MCV2 is given, the number of individuals targeted (denominator) and the number of individuals vaccinated (numerator). For the 11 year period ( ) for which there are data, the first step of the 1 WHO. Measles vaccines : WHO Position Paper. Weely Epidemiological Record, No. 35, 2009, 84, WHO. Measles and Rubella Strategic Plan: P age
4 assignment will be to extract the country specific data on MCV2 from the JRF database and clean the data by investigating any inconsistencies and information gaps. 2. Analyze the data and build age- specific MCV2 coverage estimates: Transpose the compiled data into age- specific categories and calculate age- specific coverage rates. The person undertaking the work will have to build age- specific coverage tables from the mass of data that is currently available from the JRF but is not organized in a way that lends itself to an analysis of coverage rates. Expected Outcomes of Deliverables: Construct age- specific coverage rates for each country having MCV2 in their immunization schedule; Aggregate the above data to formulate a global coverage estimate of MCV2; Propose any necessary revisions to the JRF that will improve MCV2 coverage calculations in the future; Draft generic monitoring and recording templates for countries to use for MCV2; In a seminar present the preliminary results of the work to the IVB staff for critique and discussion; Collaborate on the drafting of a manuscript on the above work for submission to a peer- reviewed journal. Skills Necessary: Fluency in oral and written English Proficiency with Microsoft Excel and managing large data sets Strong analytical skills Self- initiative with careful attention to detail 4 P age
5 C. Supporting the Introduction and Use of Vaccines Through the Collection, Analysis and Reporting of Global VPD Surveillance Data Mentor: Mary Agocs Vaccines are one of the most cost- effective interventions to improve public health. In addition to the six traditional vaccines against diphtheria, tetanus, pertussis, polio, measles and tuberculosis (BCG), recent years have seen a dramatic increase in the number of new vaccines that can provide additional prevention of untimely deaths and disabilities. These include vaccines against hepatitis B, invasive Haemophilus influenzae type b (Hib) disease, pneumococcus, rotavirus, Human Papilloma Virus (HPV) and rubella. As countries are considering including these new and relatively expensive vaccines into their immunization schedules, decision makers require reliable data to determine how to best allocate their resources in support of public health programmes. Additionally, vaccine coverage monitoring is critical in order to evaluate the effectiveness of vaccine delivery programmes and to evaluate vaccine impact 5-30 years after immunization. During the past several years, various data collection systems have been established to provide surveillance data for decision makers around the introduction of new and underutilized vaccines. These various systems are being transitioned into the WHO surveillance reporting network and are now allowing global comparisons to be made between countries and over time. During this process, due attention is being paid to ensuring that data are collected in a standardized and routine manner for quality assurance and data comparison purposes. Scope of Work for VPD Surveillance: Assist in the development of global standard operating procedures for the invasive bacterial vaccine preventable network; Compare changes over time in reported new vaccines surveillance data for rotavirus and invasive bacterial vaccine preventable diseases (IB- VPD) from 2008 to present to identify any significant changes, globally, regionally or by country; Develop a surveillance performance report card that can be visually used to monitor data quality by country; Assist in developing and implementing a plan to better communicate the surveillance data to partners and Ministries of Health; Develop or further refine a data collection template to allow standardized collection of serotype and genotype data from Regional Reference Laboratories; and Synthesize the existing information to provide recommendations in how to target efforts to strengthen surveillance and to better understand the surveillance data. Note: Discussions would be held with the selected candidate to determine a mutually agreeable and specific scope of work that draws from the above points. Skills Necessary: Languages: Fluency in English. Working knowledge of French desirable. Computer skills: Proficiency with Microsoft Excel, Word, PowerPoint and e- mail. Experience with database software such as Microsoft Access desirable. Professional Experience: An understanding of surveillance systems and their strengths and limitations. Training and experience in quantitative data analysis. Useful, but not required: Experience with collection or analysis of survey data; experience evaluating vaccination coverage. 5 P age
6 D. Strengthening the evidence- base of WHO immunization policy recommendations Department of Immunization, Vaccines and Biologicals (IVB), Immunization Policy Unit Mentor: Philippe Duclos Background: In accordance with WHO s mandate to provide technical guidance to Member States on health policy, the Immunization Policy Unit is charged with developing global immunization policy recommendations. In this context, the Unit carries out the secretariat function for the Strategic Advisory Group of Experts (SAGE) on immunization which is the main global advisory committee on immunization and provides policy recommendations on the use of vaccines. The Unit also publishes a series of vaccine position papers for vaccine preventable diseases that have an international public health impact. The papers follow the recommendations of SAGE and are submitted to an extended review process both inside and outside of WHO prior to publication. During the implementation of the Strategic Plan, IVB convened an independent Stakeholder s Panel representing the global immunization community to determine the impact of policy recommendations and standards set by WHO and formulated by its key advisory committees. The panel concluded that WHO vaccine advisory committees play an increasingly central role in determining global vaccine policy, especially in developing countries, and recommended that WHO take immediate steps to build on this success. In response to the stakeholders' panel recommendations, the Immunization Policy Unit has improved the policy- setting processes and communications, and continues to further strengthen the processes for evidence- base of the policy recommendations work. Scope of Work: The IVB Department is now recruiting an intern to work under the supervision of the Senior Health Adviser within the Immunization Policy Unit to assist in improving the formulation of evidence- based policy recommendations and the functioning of SAGE. The planned activities include: Conducting systematic reviews of literature to assist SAGE working groups with preparation and review of evidence particularly with respect to vaccine efficacy and safety for updated WHO vaccine position papers (most likely in the area of varicella, co- administration of vaccines and/or delayed immunization schedules) Developing GRADE tables by applying WHO guidelines to assess the strength of evidence in support of key recommendations Conducting a survey of practices of the WHO regional technical advisory groups Implement a survey looking at the impact of WHO recommendations Supporting the organization of the SAGE meetings and teleconferences and contribute to adjustments of SAGE standard operating practices The specific activities and project(s) will be agreed with the intern and will depend on period set for the internship, its duration, as well as the skills and interest of the incumbent. Skills Necessary: Proficiency with literature searches on PubMed and preferably other databases Background in epidemiology An understanding of GRADE methodology and its strengths and limitations would be a plus but not a requirement Fluency in English Working knowledge of another official HQ language including Arabic, Chinese, French, Spanish or Russian would be an asset Proficiency with , web and MS Office software (Word, Excel, PowerPoint) Capacity to analyse data Good writing skills Tact and ability to work with people of different technical and cultural backgrounds 6 P age
7 E. Economics of vaccines and immunizations Mentor: Miloud Kaddar, Senior Adviser, Health Economist, WHO/FCW- IVB- EPI. Geneva Background: The WHO Immunization, Vaccines & Biologicals Department seeks an intern to be part of an exciting project on vaccine pricing and to work under the supervision and guidance of WHO technical staff within EPI team on the following topics: Vaccine price and pricing: theory, policies and practices at country and global level Immunization financing and vaccine procurement in low and middle income countries The intern will be part of the Vaccine Product, Price and Procurement (V3P) Project working team and would be expected to conduct the following tasks: 1. Data collection and analysis 2. Review technical notes and reports 3. Interact with experts, teams, countries and partners 4. Consolidate the findings from the various sources, studies and country data and reports 5. Prepare draft notes and papers for discussion and attend meetings with technical WHO & partners staff 6. Update web pages, country fact sheets and databases 7. Attend technical meetings and make technical presentations 8. Participate in workshops and technical seminars at WHO/HQ. Education and skills: Excellent knowledge of statistics and economic concepts and tools Good knowledge of public health concepts and issues Fluency in writing in English is essential. Ability of synthesize information from different sources and consolidate in a meaningful manner. Proficiency with database and excel processing software, Some experience with developing countries and familiarity with global health initiatives and immunizations will be appreciated 7 P age
8 F. Support to analyse survey data and develop an article on experiences with obtaining consent for vaccination of school- going children and adolescents Mentor: Paulus Bloem Background: In 2009, WHO issued a new recommendation on HPV vaccination to 9 to 13 year olds which is a target group outside the normal ages covered by routine immunization in many developing countries. In addition to HPV vaccine, the number of vaccinations that (may) target older children and adolescents is increasing. Examples of other vaccines include Rubella, Measles, DTP booster, Hep B, among others. This presents new challenges for immunization programmes and health workers, such as the issue of consent. In childhood vaccination, one of the parents is normally present when the child is vaccinated and the presence of the parent is considered an expression of consent. When vaccinating older children and adolescents, this often takes place in settings and at times where the parent is not present, such as during school. According to regulations in most health systems, children and adolescents in the ages between 6 and 17, are not themselves allowed to provide consent for vaccination and most other medical interventions. Some process is therefore in place to deal with the issue of informed consent. A recent WHO report on HPV delivery (2012) noted that for younger adolescents (including 9-13 year olds), parents play an important role. Thus, parents need to be fully engaged in decision- making regarding their children s use of health services. This may include taking them to health facilities. In addition, in most countries, parents need to provide consent or approve that their young adolescent may receive health services. The report also noted that there were practical concerns with the informed consent process that may affect the vaccination process and outcomes. Based on these concerns with HPV vaccination and the growing number of vaccines recommended for older children, WHO decided to review and summarize the experience and various options for dealing with obtaining consent for any vaccine given to 6-17 year olds. Between July and December 2012, a key informant survey was carried out among EPI managers in selected countries that had reported to WHO that they provided vaccination to the relevant age group in their schedule. For the European region, where a large number of countries perform vaccinations in older children, the survey questionnaire was expanded and made available for online data entry. By end November 2012 information from 30 countries has been gathered, while information from Africa and Europe is being expected from up to more countries over the coming month. Scope of Work: The WHO Immunization, Vaccines & Biologicals (IVB) Department seeks an intern to work under the supervision of WHO technical staff within the (Expanded Programme on Immunization (EPI) team to support two components of work: 1. Analyse and organize the data collected from the countries: Preliminary data analysis has taken place towards the development of a guidance note. The person will be requested to carry out more in- depth analysis of the whole dataset, including where possible carry out (limited) statistical analysis of relationships between consent methodology, vaccine schedules and coverage levels. 2. Develop an article for a peer review journal on the findings: Based either on the European subset or full set of data, develop an article for a peer review journal. Different stages will include identification of journal and requirements; carrying out a literature review to include relevant references; writing the draft article and incorporate comments from collaborators in WHO HQ and others. Prepare a version of the paper including graphs and literature review that is ready to be submitted to the peer- reviewed journal. Due to the time delay in getting the paper finished, the person is invited to remain involved in the finalization of the article up to the point of final acceptance in the journal and will be co- author. Expected Outcomes of Deliverables: Analyses of full data set organized in background document; 8 P age
9 Seminar presentation on the findings and results of the analysis; Annotated outline of the article based on discussions with authors; First draft article for circulation; Final article ready to submission to a peer- reviewed journal. Skills Necessary: Fluency in oral and written English Proficiency with Microsoft Excel and managing data Strong analytical skills Self- initiative with careful attention to detail 9 P age
10 G. The broader economic impact of vaccines Mentor: Raymond Hutubessy Background: Over the next decade several new vaccines will become available against infectious diseases of major public health importance. Public health decision- makers will need to make choices, between vaccines and between other preventive interventions. New vaccines (e.g. pneumococcal, rotavirus and human papillomavirus vaccines) are more expensive compared to the dollar cents traditional vaccines costs (e.g. diphtheria, tetanus, pertussis, polio, measles and tuberculosis) while countries increasingly have to carry the full costs of vaccination programs. Among other things decision makers need information on the relative cost- effectiveness (CE) of vaccines compared to other preventive interventions. However, traditional view of cost- effectiveness analysis (CEA) is too narrow which may lead to substantial underestimates of the value of some vaccinations. There are several pathways through which vaccinations can affect economic activity both at the individual and population level. Vaccination results in lifetime productivity gains as it prevents diseases that can cause cognitive impairment, lead to physical handicap, or reduce school attendance. As many vaccinations will significantly will reduce child mortality from infectious diseases, fertility rates will be reduced which will lead to decreasing ratio of economically dependent people in a population, which increases the labor force and savings. In order to assist countries in the collection of local evidence WHO is embarking on a broader economic impact of vaccines consultation meeting with the objective 1. to obtain an overview and feedback of existing and innovative measurement methods and tools 2. to propose generic manuals for quantifying the broader economic burden of vaccines for potential users in LMIC. Scope of Work: In preparation to the above mentioned consultation the WHO Initiative for Vaccine Research seeks an intern to work under the supervision of WHO technical staff of the operational research group to undertake a project with the following aims: Assist in synthesizing preliminary results from economic studies of the broader impact of vaccines issued by WHO in 2013 Contribute to the WHO framework and practical tool development of quantifying the broader economic impact of vaccines Facilitate in the preparation of the WHO Consultation meeting in 2013 with health economic experts It is intended that a review publication will arise from this project. Skills required: Fluency in English Proficiency with Microsoft Excel, and word processing software Proficiency with literature searches on PubMed and preferably other databases Training and experience in health economics 10 P age
The Johns Hopkins Vaccine Initiative Johns Hopkins Bloomberg School of Public Health
WHO Internships (Terms of Reference) for VIEW Scholars Program January 2010 A. Examining approaches to collecting and analyzing HPV vaccine coverage data B. County level burden of disease estimates for
More informationPAVE Internship descriptions
PAVE 2019-2020 Internship descriptions WHO IVB - Geneva, Switzerland WHO IVB 1: Timeliness of two-dose measles schedules and vaccination provided to children > 12 months of age WHO IVB 2: Modelling and
More informationMonitoring results: goals, strategic objectives and indicators
page 108 Monitoring results: goals, strategic objectives and indicators 6. SURVEILLANCE Strategic Objective 4: strong immunization sytems are an integral part of a well-functioning health system. Indicator
More informationHow to present the European Vaccine Action Plan (EVAP)
How to present the European Vaccine Action Plan 2015-2020 () HOW TO USE THIS DOCUMENT By adopting the European Vaccine Action Plan 2015-2020 () in September 2014, all Member States of the WHO European
More informationChallenges of building a new vaccine delivery platform for LMICs
Challenges of building a new vaccine delivery platform for LMICs Terri B. Hyde, MD MPH Immunizations Systems Branch, GID, CDC 23 March 2017 Immunization in the Elderly Geneva, Switzerland What has been
More informationTargeted Diseases and Immunization. Strategic plan
Targeted Diseases and Immunization Strategic plan 2008-2013 Communicable Diseases Unit WHO Regional Office for Europe Mission To provide technical support to WHO European Region Member States to ensure
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationEstablishing a second-year-of-life (2YL) healthy child visit
Establishing a second-year-of-life (2YL) healthy child visit Dr Rudi Eggers Presentation to the Global Vaccines and Immunization Research Forum Sandton, 15 March 2016 Session Objectives Provide an overview
More informationFifth report of Committee A
SIXTY-EIGHTH WORLD HEALTH ASSEMBLY (Draft) A68/73 26 May 2015 Fifth report of Committee A (Draft) Committee A held its twelfth and thirteenth meetings on 25 May 2015 under the chairmanship of Dr Eduardo
More informationTERMS OF REFERENCE. Regional Immunization Program. Department of Family, Gender and Life Course
TERMS OF REFERENCE Regional Immunization Program Department of Family, Gender and Life Course 1/11/2017 TERMS OF REFERENCE Regional Immunization Program I. Description and Overall Purpose of the Evaluation
More informationPROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary
CBD Distr. GENERAL UNEP/CBD/COP/11/31 30 July 2012 ORIGINAL: ENGLISH CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY Eleventh meeting Hyderabad, India, 8 19 October 2012 Item 3.2 of
More informationBack to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office
Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office SAGE, Geneva 27 October 2009 Rebecca Martin Targeted Diseases and
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationReport of the survey on private providers engagement in immunization in the Western Pacific region
Report of the survey on private engagement in immunization in the Western Pacific region Ananda Amarasinghe, MD, Laura Davison MIA, Sergey Diorditsa, MD Expanded Programme on Immunization, WHO Regional
More informationGlobal Health Policy: Vaccines
Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY
More informationThe Financial Sustainability of New Vaccine Introduction in the Poorest Countries :
The Financial Sustainability of New Vaccine Introduction in the Poorest Countries : Evidence from the First Phase of GAVI (Global Alliance for Vaccines and Immunization) Patrick Lydon lydonp@who.int Session:
More informationHealthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.
Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy
More informationMessage from. Dr Samlee Plianbangchang Regional Director, WHO South-East Asia. At the. Regional Review Meeting on Immunization
Message from Dr Samlee Plianbangchang Regional Director, WHO South-East Asia At the Regional Review Meeting on Immunization 19-23 July 2010 WHO/SEARO, New Delhi Regional Review Meeting on Immunization
More informationOVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE
OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationused for HPV vaccine delivery to identify best practices and inform efforts to improve HPV vaccine coverage nationwide.
Gavi Full Country Evaluations Findings Summary of recommendations Ministry of Finance» Be involved at all stages of planning for new vaccine introductions. Ministry of Health» Conduct a survey to fully
More informationDiabetes Action Now. Consultation on a new WHO-IDF programme
World Health Organization Consultation on a new WHO-IDF programme A call for your views This document announces a new World Health Organization International Diabetes Federation (WHO-IDF) programme,. The
More informationTowards the Achievement of GHSA 2024 s Overarching Targets
정보화파트업무계획 [GHSA] Immunization Towards the Achievement of GHSA 2024 s Overarching Targets 2016년추진업무및 2017년업무계획 ( 사업관리 ) 7 th November 2018 Korea Centers for Disease Control and Prevention I. Overview Contents
More informationVaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO
Vaccine Preventable Disease Surveillance: Overview Thomas Cherian, WHO Global Framework on Immunization Monitoring and Surveillance (GFIMS) l An extension of the GIVS, published on December 07 - http://www.who.int/immunization/en/
More informationAfghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision
Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data
More informationVaccine Finance. Overview of stakeholder input and NVAC working group draft white paper. Walt Orenstein, MD
Vaccine Finance Overview of stakeholder input and NVAC working group draft white paper Walt Orenstein, MD Consultant to the National Vaccine Program Office July 24, 2008 Number of Vaccines in the Routine
More informationNational Vaccine Plan: From Strategy to Implementation
National Vaccine Plan: From Strategy to Implementation July 26, 2011 Sarah Landry Senior Advisor, National Vaccine Program Office Office of the Assistant Secretary for Health Department of Health and Human
More informationVaccine Decision-Making
Key Points Vaccine Decision-Making * Decisions on introducing new vaccines have long-term implications for immunization costs as well as logistics systems and service delivery. The choice of vaccine presentation
More informationOverall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
More informationExpanded Programme on Immunization (EPI)
Sri Lanka 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationChallenges and solutions in making evidence-based national vaccination policies and recommendations
Challenges and solutions in making evidence-based national vaccination policies and recommendations Philippe Duclos, WHO 15th ADVAC, Les Pensières, Veyrier du Lac, May 19, 2014 Developing evidence-based
More informationPertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months.
Program Management 61_5 The wp vaccines have a considerably lower price than ap vaccines and, where resources are limited and the vaccine is well accepted by the local population, wp vaccine remains the
More informationExpanded Programme on Immunization (EPI)
Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing
More informationThe Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
More informationExpanded Programme on Immunization (EPI)
Timor-Leste 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationMidterm Review of the Global Measles and Rubella Strategic Plan W. A. Orenstein, MD SAGE Geneva, 19 October 2016
Midterm Review of the Global Measles and Rubella Strategic Plan 2012 2020 W. A. Orenstein, MD SAGE Geneva, 19 October 2016 1 Outline Strategic Plan 2012-2020 Progress toward milestones and goals Objectives
More informationMeasles and Rubella Global Update SAGE 19 October 2017
Measles and Rubella Global Update SAGE 19 October 2017 Alya Dabbagh WHO HQ, IVB/EPI Global update Overview Regional progress and challenges M&RI Midterm Review updates Economics of measles and rubella
More informationWHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated
More informationCountdown to 2015: tracking progress, fostering accountability
Countdown to 2015: tracking progress, fostering accountability Countdown to 2015 is a global movement to track, stimulate and support country progress towards achieving the health-related Millennium Development
More informationGOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights
GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION (indicator G2.2) Highlights As of December 2014, 140 Member States had introduced rubella vaccines; coverage, however, varies from 12% to 94% depending on region.
More informationMeeting of the Strategic Advisory Group of Experts (SAGE) on Immunization Agenda October 2018 CICG, Geneva, Switzerland Version: 19 October 2018
Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization Agenda 23-25 October 2018 CICG, Geneva, Switzerland Version: 19 October 2018 Tuesday, 23 October 2018 Time Session 09:15 Welcome
More informationImmunize children and adults against vaccine-preventable disease in
PERFORMANCE PLAN PHD/CHSB & SH CHSB: Yvette Griffin x1274, Teresa Moberly x1242 SHB: Helen Nace x1655, Jennifer Toma x8156 Program Purpose Program Information Immunize children and adults against vaccine-preventable
More informationImmunize children and adults against vaccine-preventable disease in
PHD/CHSB & SH CHSB: Yvette Wright x1274, Teresa Moberly x1242 SHB: Helen Nace x1655, Jennifer Toma x8156 Program Purpose Program Information Immunize children and adults against vaccine-preventable disease
More information1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector
1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share
More informationHistory and aims of immunisation. Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8
History and aims of immunisation Dr Anna Clarke Department of Public Health Dr. Steevens Hospital Dublin 8 Objectives To examine the history of immunisation To explain the aim of immunisation To develop
More informationSAGE recommendations on non-specific effects of vaccines and their implementation
SAGE recommendations on non-specific effects of vaccines and their implementation Andrea Vicari Initiative for Vaccine Research Immunization, Vaccines and Biologicals Topics Process of developing immunization
More informationExpanded Programme on Immunization (EPI)
Indonesia 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles
More informationPeer counselling A new element in the ET2020 toolbox
shutterstock Peer counselling A new element in the ET2020 toolbox Information Note. Main characteristics of the peer counselling tool Peer learning in the context of the education cooperation at EU level
More informationWorld Immunization Week 2013
CAMPAIGN ESSENTIALS World Immunization Week 2013 Protect your world get vaccinated World Health Organization 2013. All rights reserved. Document number: WHO/World-Immunization-Week/2013.1 This document
More informationMonitoring of the achievement of the health-related Millennium Development Goals
SIXTY-THIRD WORLD HEALTH ASSEMBLY WHA63.15 Agenda item 11.4 21 May 2010 Monitoring of the achievement of the health-related Millennium Development Goals The Sixty-third World Health Assembly, Having considered
More informationREGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition
REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC second edition World Health Organization 2014 The designations employed and the presentation of the material in
More informationFrom development to delivery: Decision-making for the introduction of a new vaccine
From development to delivery: Decision-making for the introduction of a new vaccine Prince Mahidol Award Conference Bangkok, Thailand 1-2 February 2007 Dr. J.M. Okwo-Bele Department of Immunization, Vaccines
More informationVACCINES TRIUMPHS AND TRIBULATIONS. William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine
VACCINES TRIUMPHS AND TRIBULATIONS William Schaffner, MD Chairman, Department of Preventive Medicine Vanderbilt University School of Medicine Never in the history of human progress has a better and cheaper
More informationThank you for joining, the M&RI webinar will begin shortly
Thank you for joining, the M&RI webinar will begin shortly Please mute your phone or microphone Please do not place the call on hold If you have difficulty with the quality of the connection then here
More informationGovernment of Bangladesh
Gavi Full Country Evaluations Findings Summary of recommendations Expanded Programme on Immunization Government of Gavi Secretariat With country-level partners, target efforts on low coverage areas and
More informationReport to the. GAVI Alliance Board June 2013
Report to the GAVI Alliance Board 11-12 June 2013 Subject: Report of: Authored by: Risk Management Update Helen Evans, Deputy CEO Ciara Goldstein, Analyst, Performance Management and Adrien de Chaisemartin,
More informationGavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework
Gavi, the Vaccine Alliance - Health System and Immunisation Strengthening (HSIS) Support Framework I. Purpose This Framework sets out the principles and several essential requirements for Gavi s Health
More informationSelected vaccine introduction status into routine immunization
Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF
More informationIOM Committee on Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule
IOM Committee on Assessment of Studies of Health Outcomes Related to the Recommended Childhood Immunization Schedule Bruce Gellin, MD, MPH Director, National Vaccine Program Office Deputy Assistant Secretary
More informationUNICEF Nepal Country Office (NCO) Terms of Reference
UNICEF Nepal Country Office (NCO) Terms of Reference National Consultancy for National Integrated Micronutrients Guideline Development and updating training package on Micronutrients (Vitamin A Deficiency,
More informationGlobal health sector strategies on HIV, viral hepatitis and sexually transmitted infections ( )
Regional Committee for Europe 65th session EUR/RC65/Inf.Doc./3 Vilnius, Lithuania, 14 17 September 2015 2 September 2015 150680 Provisional agenda item 3 ORIGINAL: ENGLISH Global health sector strategies
More information3. CONCLUSIONS AND RECOMMENDATIONS
3. CONCLUSIONS AND RECOMMENDATIONS 3.1 Polio Endgame Strategy Conclusions 1. The TAG welcomes the RCC conclusion that Western Pacific Region maintains its polio-free status, and commends China for the
More informationExpanded Programme on Immunization
1 Expanded Programme on Immunization Strategic issues Immunization is a cost-effective public health intervention that has dramatically reduced disease, disability and death in the Western Pacifi c Region.
More informationThe power of partnership: the GAVI Alliance Board
The power of partnership: the GAVI Alliance Board 1 GAVI s mission To save children s lives and protect people s health by increasing access to immunisation in poor countries Strategic goals 2011 2015!
More informationGlobal Immunizations & UNICEF s Role Dr. Robin Nandy Principal Advisor & Chief of Immunizations UNICEF Headquarters
Global Immunizations & UNICEF s Role Dr. Robin Nandy Principal Advisor & Chief of Immunizations UNICEF Headquarters UNICEF Vaccine Industry Consultation Copenhagen 5 October 2017 Outline Status & directions
More informationGlobal reporting system for hepatitis (GRSH) project description
Global reporting system for hepatitis (GRSH) project description Contents 1. Background... 2 2. Target audience for this document... 2 3. Data to be reported through the Global Reporting System for Hepatitis...
More information2016/17 Vaccination and Immunisation list of additional services and enhanced services
2016/17 Vaccination and Immunisation list of additional services and enhanced services 2016/17 Vaccination and Immunisation list of additional services and enhanced services Version number: 1 First published:
More informationImmunization Report Public Health September 2013
Immunization Report Public Health September 2013 Daycare, school entry and school program immunization enrollment rates, up to 2012 Table of Contents 1. Introduction... 2 2. Data Source... 2 3. Limitations...
More information2017/18 Immunisation programmes list of additional and enhanced services
2017/18 Immunisation programmes list of additional and enhanced services 2017/18 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2017 Prepared
More informationManitoba Health, Healthy Living and Seniors
Manitoba Health, Healthy Living and Seniors Manitoba Annual Immunization Surveillance Report, 2012 and 2013 January 1, 2012 to December 31, 2013 with 5-year average comparison (January 1, 2007 to December
More informationImmunization coverage and exemptions among Ontario s school pupils for : Findings and implications for future information systems
Immunization coverage and exemptions among Ontario s school pupils for 2011 12: Findings and implications for future information systems GH Lim, MA McIntyre, S Wilson PHO Ground Rounds August 20, 2013
More informationTotal population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093
DPR Korea 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering -5. A standing national technical advisory group on immunization (NTAGI) with formal
More informationGAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012
GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012 ADRESSING CHALLENGES TO SUSTAINABLE NEW VACCINE INTRODUCTION: PERSPECTIVE FROM MONGOLIA N.UDVAL, MD, Sc D MINISTER OF HEALTH MONGOLIA CONTENT
More informationVaccine-Preventable Diseases in Colorado s Children 2009 Sean O Leary MD, Carl Armon PhD, Joni Reynolds, RNC, MSN, James Todd MD
State of the Health of Colorado s Children Vaccine-Preventable Diseases in Colorado s Children 29 Sean O Leary MD, Carl Armon PhD, Joni Reynolds, RNC, MSN, James Todd MD Vaccines have been highly effective
More informationPreventing Cervical Cancer Through Effective Data Use: Practical Tools
Preventing Cervical Cancer Through Effective Data Use: Practical Tools Jenn Drummond, MPH IDCCP Lead Technical Advisor Megan Wysong, MPH M&E Team Lead, Jhpiego/USA John E. Varallo, MD, MPH Senior Technical
More informationAccess to vaccination in GAVI countries and at global level
Access to vaccination in GAVI countries and at global level Stefano Malvolti Director, Vaccine Implementation GAVI Alliance 15th ADVANCED COURSE OF VACCINOLOGY May 12, 2014 Global progress to MDG 4 for
More informationNHS GRAMPIAN IMMUNISATION PROGRAMMES ANNUAL REPORT 2010/11
NHS GRAMPIAN IMMUNISATION PROGRAMMES ANNUAL REPORT 2010/11 NHS GRAMPIAN IMMUNISATION STEERING GROUP March 2012 1 Table of Content 1. Purpose of this report.3 2. Uptake of immunisation: key points during
More information2018/19 Immunisation programmes list of additional and enhanced services
2018/19 Immunisation programmes list of additional and enhanced services 2018/19 Vaccination and Immunisation list of additional and enhanced services Version number: 1 First published: April 2018 Prepared
More informationNote that the subject may be known by different names in different countries
CALL FOR EXPRESSION OF INTEREST FOR TECHNICAL PROPOSALS TO MEASURE DELIVERY OF COMPREHENSIVE SEXUALITY EDUCATION IN EASTERN AND SOUTHERN AFRICA: AN ANALYSIS OF PROGRESS Summary of task: to develop a regional
More informationTaking vaccine effectiveness into public health decision making: The ProVac Example
http://www.paho.org/provac Taking vaccine effectiveness into public health decision making: The ProVac Example Evaluating dengue effectiveness workshop June 12 th, 2014 Washington, DC Cara Bess Janusz
More informationIn the Name of God, the Compassionate, the Merciful. Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION.
In the Name of God, the Compassionate, the Merciful Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION on the FIRST EMIRATES INTERNATIONAL CONFERENCE ON VACCINATION Dubai,
More informationMultisectoral action for a life course approach to healthy ageing
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY Provisional agenda item 14.4 21 March 2014 Multisectoral action for a life course approach to healthy ageing 1. The attached document EB134/19 was considered and noted
More informationMedInform. Ethical and healthcare considerations in relation to mandatory vaccination - Bulgarian perspective. Literature Review
DOI: 10.18044/Medinform.201632.506 Ethical and healthcare considerations in relation to mandatory vaccination - Bulgarian perspective Alexandrina Vodenitcharova Faculty of Public Health, Medical University
More informationPolio post-certification strategy
1 Polio post-certification strategy SAGE Meeting, Geneva, 17 April 2018 Michel Zaffran, Director, Polio Eradication, WHO On Behalf o the GPEI Polio Eradication and Endgame Strategy 1. Poliovirus detection
More informationProduct Development for Vaccines Advisory Committee:
Product Development for Vaccines Advisory Committee: Highlights from the 2016 year of vaccine development SAGE, October 2016 David C. Kaslow, MD Chair, Product Development for Vaccines Advisory Committee
More informationDaycare, school entry and school program immunization report September Data for school years 2012/13 to 2014/15
Daycare, school entry and school program immunization report September 2015 Data for school years 2012/13 to 2014/15 Table of Contents Contents 1. Introduction... 0 2. Data Source... 1 3. Limitations...
More informationGlobal landscape analysis and literature review of 2 nd Year of Life immunization platform
Global landscape analysis and literature review of 2 nd Year of Life immunization platform Global Vaccine and Immunization Research Forum 15-17 March 2016 Johannesburg, South Africa Imran Mirza; Celina
More informationTable 1: Basic information Total population 25,030, (per 100,000 LB) Division/Province/State/Region 11. District 210
EPI history EPI launched in 980 HepB vaccine introduced in 003 AD syringes introduced in 003 HepB birth dose introduced in 004 DTP-HepB vaccine introduced in 006 MCV introduced in 008 DTP-Hib-HepB vaccine
More informationRequest for Proposals: Consultancy Evaluation, Toolkits and Economic Impact of the 22nd International AIDS Conference
Request for Proposals: Consultancy Evaluation, Toolkits and Economic Impact of the 22nd International AIDS Conference Proposals will be accepted until Friday 6 April 2018 1. About the International AIDS
More informationTerms of Reference Review of Save the Children Norway s work to strengthen child protection systems
Terms of Reference Review of Save the Children Norway s work to strengthen child protection systems 1. Background Save the Children is the world s leading independent organization for children. Our vision
More informationWorld Health Organization. A Sustainable Health Sector
World Health Organization A Sustainable Health Sector Response to HIV Global Health Sector Strategy for HIV/AIDS 2011-2015 (DRAFT OUTLINE FOR CONSULTATION) Version 2.1 15 July 2010 15 July 2010 1 GLOBAL
More informationAgenda Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) 1 3 April 2014 CCV/CICG, Geneva
Version: 14 March 2014 Agenda Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) 1 3 April 2014 CCV/CICG, Geneva Tuesday, 1 April 2014 Time Session Purpose of session, target outcomes
More informationSustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationVERSION APPROVAL PROCESS NUMBER 1.0 Nina Schwalbe, Managing Director, Policy and Performance
Version No.: 1.0 Page 1 / 5 DOCUMENT ADMINISTRATION VERSION APPROVAL PROCESS DATE NUMBER 1.0 Nina Schwalbe, Managing Director, and Performance Reviewed by: GAVI Programme 23 April 2012 and Committee Approved
More informationAddendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG)
Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Background India was certified polio-free along with 10 other countries of WHO South-East Asia Region
More informationHow does Gavi make vaccine investment decisions?
How does Gavi make vaccine investment decisions? Judith Kallenberg Global Vaccine and Immunization Research Forum Johannesburg, South-Africa, 16 March 2016 www.gavi.org Vaccine Investment Strategy (VIS)
More informationTable 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB)
EPI history EPI started in 978 EPI re-structured in March 000 DTP-HepB vaccine introduced in 007 DTP-Hib-HepB)vaccine introduced in 0 MR vaccine introduced in Feb 06 Second dose of MR introduced in Feb
More informationGlobal, regional and national strategic planning for viral hepatitis prevention and control
Global, regional and national strategic planning for viral hepatitis prevention and control Dr Antons Mozalevskis WHO Regional Office for Europe VHPB Baltic Meeting 19 20 November 2015 Riga, Latvia Presentation
More informationEconomic Evaluation. Defining the Scope of a Costeffectiveness
Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes
More informationPapillomavirus Rapid Interface for Modelling and Economics Tool. User Manual
Papillomavirus Rapid Interface for Modelling and Economics Tool User Manual List of abbreviations DALYs disability adjusted life years GDP HPV IARC gross domestic product human papillomavirus International
More information